“SputnikV exhibits the most secure profile amongst #COVID vaccines used within the Buenos Aires province in Argentina, no deaths associated to vaccination recorded – the province Well being Ministry,” tweeted Sputnik V.
There have been no deaths associated to the Russian vaccine, and most post-vaccination occasions have been gentle, equivalent to fever, complications, and ache on the website of utility.
The examine confirmed that the Occasions Supposedly Attributable to Vaccination or Immunization (ESAVI) have been principally gentle. Among the many most frequent are fever (47 per cent), complications (45 per cent), myalgias and arthralgias (39.5 per cent) and ache (46.5 per cent) and swelling (7.4 per cent) within the space the place the injection, stated the Buenos Aires province Well being Ministry, in a press release.
The target of the Buenos Aires investigation was to explain the prevalence of ESAVI notified to the Built-in Argentine Well being Info System (SIISA) after the applying of the Russian vaccine in opposition to COVID-19 within the province of Buenos Aires since December 29, 2020, marketing campaign begin day was June 3, 2021.
In that interval, 2.8 million doses of Sputnik V vaccine have been utilized; 1.3 million from Sinopharm and 0.9 million from Covishield/AstraZeneca with a extreme ESAVI price (product-related) per million utilized doses of 0.7; 0.8 and three.2 respectively, stated the assertion.
The investigation of every ESAVI includes classifying it in keeping with a sequence of classes established by the World Well being Organisation (WHO) and Pan American Well being Organisation (PAHO).
In the meantime, on WHO concern over Sputnik V coronavirus vaccine points with the filling of vials at one plant, the Pharmastanfar – UfaVITA stated that the problems didn’t relate to the security or efficacy of the vaccine itself, the plant is accountable just for pouring into vials doses of Sputnik V vaccine produced elsewhere.
WHO didn’t increase any questions in regards to the security and efficacy of the produced and completed vaccine because the “Sputnik V” vaccine undergoes strictest double high quality output management of the Gamaleya Institute and the Russian well being regulator (Federal Healthcare Service – Roszdravnadzor), stated OJSC Pharmstandard-UfaVITA assertion.
Furthermore, WHO interim inspection didn’t establish any essential points with the precise vaccine’s manufacturing, high quality, scientific research, attainable negative effects, nor with the double high quality output management by each the Gamaleya Institute and the Russian well being regulator. As a substitute, WHO inspectors’ consideration was centered on solely 4 technical points principally associated to one of many filling traces which have all been subsequently absolutely addressed, stated the assertion.
Additional, OJSC Pharmstandard-UfaVITA invited WHO for an additional inspection.